Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Sera Prognostics, Inc.NASDAQ: SERA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $835K fell 44.1% year over year, behind the -34.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 18.1% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.

Context

  • Stock-based compensation amounted to 6308.6% of revenue in FY2025, down 2799.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -44.1% toward the trailing-twelve-month pace of -34.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$835K-18.1% QoQ
Last fiscal yearDec 2025
$5.11M-27.1% YoY
LTMMar 2026
$4.45M-34.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.1%——
1 year-27.1%——
3-year CAGR+0.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
5.11M USD
Year-over-year change
-27.1%
4-year CAGR
+13.0%

Stock-Based Compensation vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.7% is the 6th highest of 8, against a peer median of +30.3%.
  • Stock-based compensation amounts to 7810.5% of revenue for SERA, versus a peer median of 68.1%.
SERA Competitors
Stock-Based Compensation for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$2.3B USD+49501.8%-33.1%44751.8%
STSSSkyAI, Inc.LTM Mar 2026$109.65M USD+24888.0%+373.5%27627.6%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$6.75M CAD+101.1%+21.4%—
SRZNSurrozen, Inc.LTM Mar 2026$5.11M USD+30.3%-5.3%68.1%
HURATuHURA Biosciences, Inc.LTM Mar 2026$5M USD—+208.8%—
SERASera Prognostics, Inc.LTM Mar 2026$4.45M USD-34.7%+0.4%7810.5%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$4.21M USD+10.0%+0.1%12.3%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$1.83M USD-42.1%-16.4%—
APYXApyx Medical CorporationLTM Mar 2026$1.02M USD-69.4%-33.1%1.8%
Peer median (excluding SERA) —+30.3%-2.6%68.1%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Depreciation & Amortization659K756K900K833K940K
Deferred Income Tax00000
Stock-Based Compensation3.13M5.06M5.27M7.01M5.11M
Change in Working Capital(44K)3.55M3.52M11.28M(546K)
Accounts Receivables(3.14M)(2.97M)(5.36M)11.42M22K
Inventory00000
Accounts Payables603K352K(442K)455K(1.01M)
Other Working Capital2.49M6.17M9.32M(597K)441K
Other Non-Cash Items(372K)213K(638K)(412K)801K
Operating Cash Flow(31.64M)(34.61M)(27.19M)(14.19M)(25.62M)
Capital Expenditures(1.3M)(791K)(128K)(1.1M)(726K)
Acquisitions (Net)00000
Purchases of Investments(82.06M)(48.07M)(54.14M)(35.83M)(87.61M)
Sales of Investments800K54.4M54.4M48.68M59.84M
Other Investing Activities016K311K(1.05M)0
Investing Cash Flow(82.56M)5.55M438K11.74M(28.5M)
Debt Repayment(7.66M)(303K)(466K)(440K)(194K)
Common Stock Issued66.61M00054.22M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.66M308K1.22M3.05M0
Financing Cash Flow159.59M5K752K2.61M54.03M
Effect of Forex Changes00000
Net Change in Cash45.4M(29.05M)(26M)163K(99K)
Free Cash Flow(32.94M)(35.4M)(27.32M)(15.29M)(26.35M)

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.